Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still’s Disease: Results from the National Inpatient Sample 2016–2019
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Source
2.2. Analytic Sample
2.3. Variables
2.4. Study Outcomes
2.5. Statistical Analysis
3. Results
3.1. Patient and Hospital Characteristics
3.2. Analysis of Trends and Independent Predictors of In-Hospital LOS
3.3. Analysis of Trends and Independent Predictors of In-Hospital TOTCHG
3.4. Analysis of Trends and Independent Predictors of In-Hospital Mortality
4. Discussion
5. Limitations and Strengths
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Yamaguchi, M.; Ohta, A.; Tsunematsu, T.; Kasukawa, R.; Mizushima, Y.; Kashiwagi, H.; Kashiwazaki, S.; Tanimoto, K.; Matsumoto, Y.; Ota, T.; et al. Preliminary criteria for classification of adult Still’s disease. J. Rheumatol. 1992, 19, 424–430. [Google Scholar] [PubMed]
- Magadur-Joly, G.; Billaud, E.; Barrier, J.H.; Pennec, Y.L.; Masson, C.; Renou, P.; Prost, A. Epidemiology of adult Still’s disease: Estimate of the incidence by a retrospective study in west France. Ann. Rheum. Dis. 1995, 54, 587–590. [Google Scholar] [CrossRef] [PubMed]
- Mehta, B.Y.; Ibrahim, S.; Briggs, W.; Efthimiou, P. Racial/Ethnic variations in morbidity and mortality in Adult-Onset Still’s Disease: An analysis of national dataset. Semin. Arthritis Rheum. 2019, 49, 469–473. [Google Scholar] [CrossRef] [PubMed]
- Ravelli, A.; Minoia, F.; Davì, S.; Horne, A.; Bovis, F.; Pistorio, A.; Aricò, M.; Avcin, T.; Behrens, E.M.; De Benedetti, F.; et al. Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016, 68, 566–576. [Google Scholar] [PubMed]
- Ahn, S.S.; Yoo, B.W.; Jung, S.M.; Lee, S.W.; Park, Y.B.; Song, J.J. Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. J. Rheumatol. 2017, 44, 996–1003. [Google Scholar] [CrossRef] [PubMed]
- Franchini, S.; Dagna, L.; Salvo, F.; Aiello, P.; Baldissera, E.; Sabbadini, M.G. Adult onset Still’s disease: Clinical presentation in a large cohort of Italian patients. Clin. Exp. Rheumatol. 2010, 28, 41–48. [Google Scholar] [PubMed]
- Ravasio, R.; Giacomelli, R.; Bianchi, S. Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease. Glob. Reg. Health Technol. Assess. 2020, 7, 72–80. [Google Scholar] [PubMed]
- Franchini, S.; Dagna, L.; Salvo, F.; Aiello, P.; Baldissera, E.; Sabbadini, M.G. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010, 62, 2530–2535. [Google Scholar] [CrossRef] [PubMed]
- Al-Homood, I.A. Biologic treatments for adult-onset Still’s disease. Rheumatology 2014, 53, 32–38. [Google Scholar] [CrossRef] [PubMed]
- Nordström, D.; Knight, A.; Luukkainen, R.; van Vollenhoven, R.; Rantalaiho, V.; Kajalainen, A.; Brun, J.G.; Proven, A.; Ljung, L.; Kautiainen, H.; et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J. Rheumatol. 2012, 39, 2008–2011. [Google Scholar] [CrossRef] [PubMed]
- Nishina, N.; Kaneko, Y.; Kameda, H.; Takeuchi, T. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retrospective, single-center study. Mod. Rheumatol. 2015, 25, 401–404. [Google Scholar] [CrossRef] [PubMed]
- Vitale, A.; Caggiano, V.; Maggio, M.C.; Lopalco, G.; Emmi, G.; Sota, J.; La Torre, F.; Ruscitti, P.; Bartoloni, E.; Conti, G.; et al. Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry. Front. Med. 2022, 9, 1071732. [Google Scholar] [CrossRef] [PubMed]
- Riera Alonso, E. Adult-onset still disease. In Rheumatology; Hochberg, M.C., Ed.; Elsevier: Philadelphia, PA, USA, 2019; pp. 1437–1444. [Google Scholar]
Variable | ICD-10 CM Code |
---|---|
Rheumatoid Arthritis | M06.9 |
Polymyalgia Rheumatica | M35.3 |
Arthropathic Psoriasis | L40.5 |
Systemic Lupus Erythematosus | M32.0, M32.10, M32.11, M32.12, M32.13, M32.14, M32.15, M32.19, M32.8, M32.9 |
Ankylosing Spondylitis | M45.0, M45.1, M45.2, M45.3, M45.4, M45.5, M45.6, M45.7, M45.8, M45.9, M45.A0, M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7, M45.A8, M45.AB |
Systemic Sclerosis | M34.0, M34.1, M34.2, M34.81, M34.82, M34.83, M34.89, M34.9 |
Dermato-polymyositis | M33.00, M33.01, M33.02, M33.03, M33.09, M33.10, M33.11, M33.12, M33.13, M33.19, M33.20, M33.21, M33.22, M33.29, M33.90, M33.91, M33.92, M33.93, M33.99 |
Adult-Onset Still’s Disease | M06.1 |
Macrophage Activating Syndrome | D76.1 |
Disseminated Intravascular Coagulation | D65 |
Thrombotic Thrombocytopenic Purpura | M31.1 |
Abbreviation | |
---|---|
Adult-Onset Still’s Disease | AOSD |
National Inpatient Sample | NIS |
Total Charge | TOTCHG |
Length of Stay | LOS |
Macrophage Activating Syndrome | MAS |
Disseminated Intravascular Coagulation | DIC |
Thrombotic Thrombocytopenic Purpura | TTP |
Patient and Hospital Variables | 2016 | 2017 | 2018 | 2019 | Total |
---|---|---|---|---|---|
Observation (n) | 360 | 390 | 440 | 425 | 1615 |
Mean Age (Years) | 43.26 | 42.53 | 42.43 | 43.09 | 42.54 |
Sex (%) | |||||
Female | 62.50% | 60.26% | 54.54% | 65.88% | 60.68% |
Male | 37.50% | 39.74% | 45.45% | 34.12% | 39.32% |
Race (%) | |||||
White | 53.62% | 53.33% | 43.68% | 50.60% | 50% |
Black | 8.70% | 12.00% | 20.69% | 13.25% | 14.01% |
Hispanic | 18.84% | 20.00% | 18.39% | 21.69% | 19.75% |
Asian or Pacific Islander | 11.59% | 9.33% | 10.34% | 7.23% | 9.55% |
Native American | 0% | 0% | 0% | 1.20% | 0.32% |
Other | 7.25% | 5.33% | 6.90% | 6.02% | 6.37% |
Hospital Bed Size (%) | |||||
Small | 16.67% | 6.41% | 13.64% | 14.12% | 12.69% |
Medium | 20.83% | 28.21% | 19.32% | 15.29% | 20.74% |
Large | 62.50% | 65.38% | 67.05% | 70.59% | 66.56% |
Hospital location (%) | |||||
Rural | 4.17% | 5.13% | 4.55% | 3.53% | 4.33% |
Urban non-teaching | 1.11% | 14.10% | 6.82% | 7.06% | 9.60% |
Urban teaching | 84.72% | 80.77% | 88.64% | 89.41% | 86.07% |
Hospital Region (%) | |||||
Northeast | 31.94% | 24.36% | 30.68% | 25.88% | 28.17% |
Midwest | 20.83% | 10.26% | 18.18% | 21.18% | 17.65% |
South | 27.78% | 43.59% | 31.82% | 27.06% | 32.51% |
West | 19.44% | 21.79% | 19.32% | 25.88% | 21.67% |
In-Hospital LOS | 7.14 | 7.91 | 7.33 | 7.00 | 7.34 |
In-Hospital TOTCH | 58,575.67 USD | 76,051.32 USD | 70,365.64 USD | 67,723.78 USD | 68,415.31 USD |
Clinical Outcomes | Unadjusted OR (95% CI) | p-Value for Unadjusted OR | Adjusted OR (95% CI) | p-Value for Adjusted OR |
---|---|---|---|---|
Age | 0.02 (−0.31 to 0.74) | 0.415 | −0.01 (−0.07 to 0.05) | 0.738 |
Female | −0.71 (−2.13 to 0.70) | 0.325 | −0.64 (−2.04 to 7.61) | 0.370 |
MAS | 8.64 (1.56 to 15.73) | 0.017 | 8.99 (1.71 to 16.29) | 0.016 |
DIC | 8.07 (3.06 to 13.08) | 0.002 | 7.06 (3.87 to 10.24) | 0.000 |
TTP | −2.36 (−6.59 to 1.88) | 0.275 | −2.92 (−7.43 to 1.69) | 0.214 |
Small Hospital Size | Reference | Reference | ||
Medium Hospital Size | 0.60 (−1.68 to 2.88) | 0.607 | 1.07 (−1.21 to 3.35) | 0.303 |
Large Hospital Size | 2.49 (0.68 to 4.29) | 0.007 | 2.24 (0.02 to 4.46) | 0.042 |
White | Reference | Reference | ||
Black | 1.73 (−1.59 to 5.06) | 0.307 | 1.17 (−1.94 to 4.28) | 0.461 |
Hispanic | 0.52 (−1.08 to 2.12) | 0.527 | 0.05 (−1.73 to 1.83) | 0.953 |
Asian or Pacific Islander | 1.04 (−1.38 to 3.47) | 0.398 | 0.58 (−1.81 to 2.97) | 0.636 |
Native American | −2.79 (−3.78 to −1.80) | 0.000 | −3.99 (−7.29 to −0.68) | 0.018 |
Other | 1.41 (−0.78 to 3.60) | 0.207 | 0.77 (−1.8 to 3.3) | 0.557 |
Clinical Outcomes | Unadjusted OR (95% CI) | p-Value for Unadjusted OR | Adjusted OR (95% CI) | p-Value for Adjusted OR |
---|---|---|---|---|
Age | −154.51 USD (−888.45 to 579.64) | 0.680 | −451.73 USD (−1241.143 to 337.680) | 0.262 |
Female | −8059.47 USD (−24,504.54 to 8385.59) | 0.337 | −11,731.34 USD (−26,403.87 to 2941.182) | 0.117 |
MAS | 96,918.06 USD (2295.40 to 191,540.7) | 0.045 | 106,711.80 USD (8702.64 to 204,720) | 0.033 |
DIC | 91,840.39 USD (26,800.68 to 156,880.1) | 0.006 | 70,001.37 USD (40,274.57 to 99,728.18) | 0.000 |
TTP | −19,576.54 USD (−59,495.99 to 20,342.91) | 0.336 | −17,632.92 USD (−67,406.69 to 32,140.84) | 0.487 |
Small Hospital Size | Reference | Reference | ||
Medium Hospital Size | 35,201.61 USD (−884.8402 to 71,288.08) | 0.056 | 13,013 USD (−8626.756 to 34,652.75) | 0.239 |
Large Hospital Size | 44,539.42 USD (31,073.82 to 58,005.02) | 0.000 | 29,572.07 USD (6724.683 to 52,419.46) | 0.011 |
White | Reference | Reference | ||
Black | 18,504.43 USD (−26,598.65 to 63,607.50) | 0.421 | 19,247.78 USD (−21,198.44 to 59,694) | 0.351 |
Hispanic | 23,948.93 USD (5945.39 to 41,952.47) | 0.009 | 14,824.88 USD (−5786.466 to 35,436.230) | 0.159 |
Asian or Pacific Islander | 17,954.29 USD (−18,830.67 to 54,739.25) | 0.339 | 15,215.68 USD (−20,071.48 to 50,502.84) | 0.398 |
Native American | −34,308.14 USD (−43,211.43 to −25,404.85) | 0.000 | −47,372.49 USD (−85,894.17 to −8850.811) | 0.016 |
Other | 23,103.69 USD (−3888.60 to 50,095.98) | 0.093 | 6196.156 USD (−27,446.61 to 39,838.92) | 0.718 |
Clinical Outcomes | Unadjusted OR (95% CI) | p-Value for Unadjusted OR | Adjusted OR (95% CI) | p-Value for Adjusted OR |
---|---|---|---|---|
Age | 0.92 (0.87 to 0.98) | 0.005 | 0.85 (0.76 to 0.96) | 0.007 |
Female | 0.32 (0.03 to 3.6) | 0.355 | 0.53 (0.014 to 20.21) | 0.73 |
MAS | 33.56 (2.90 to 388.07) | 0.005 | 1.00 | |
DIC | 1.00 | 1.00 | ||
TTP | 159.50 (7.17 to 3547.65) | 0.001 | 1.00 | |
White | Reference | Reference | ||
Black | 1.00 | 1.00 | ||
Hispanic | 1.00 | 1.00 | ||
Asian or Pacific Islander | 1.00 | 1.00 | ||
Native American | 1.00 | 1.00 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mittal, S.; Schroeder, B.; Alfaki, M. Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still’s Disease: Results from the National Inpatient Sample 2016–2019. Diseases 2024, 12, 166. https://doi.org/10.3390/diseases12070166
Mittal S, Schroeder B, Alfaki M. Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still’s Disease: Results from the National Inpatient Sample 2016–2019. Diseases. 2024; 12(7):166. https://doi.org/10.3390/diseases12070166
Chicago/Turabian StyleMittal, Sushmita, Benjamin Schroeder, and Musaab Alfaki. 2024. "Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still’s Disease: Results from the National Inpatient Sample 2016–2019" Diseases 12, no. 7: 166. https://doi.org/10.3390/diseases12070166
APA StyleMittal, S., Schroeder, B., & Alfaki, M. (2024). Mortality, Length of Stay and Cost of Hospitalization among Patients with Adult-Onset Still’s Disease: Results from the National Inpatient Sample 2016–2019. Diseases, 12(7), 166. https://doi.org/10.3390/diseases12070166